Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial Extension Protocol to Add a 39 Week Follow Up to Cingal 16-02, a Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection of Cingal to Provide Symptomatic Relief of Knee Osteoarthritis

NCT03390036 is registered in ClinicalTrials.gov with Anika Therapeutics, Inc. as lead sponsor.

NCT NCT03390036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03390036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial Extension Protocol to Add a 39 Week Follow Up to Cingal 16-02, a Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection of Cingal to Provide Symptomatic Relief of Knee Osteoarthritis
Lead sponsor
Anika Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2017
Completion date
July 30, 2018
Enrollment
526 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis